Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ACAD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response NCT07284667 · Major Depressive Disorder (MDD), Depressive Disorder, Treat… ACP-211, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Recruiting | 153 | Aug 2027 | Registry ↗ |
| Nov 5, 2026 | ACP-204 in Adults With Alzheimer's Disease Psychosis NCT06159673 · Alzheimer's Disease Psychosis ACP-204, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2/3 | Recruiting | 1,074 | Jan 2028 | Registry ↗ |
| Nov 4, 2026 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis NCT07095465 · Lewy Body Dementia Psychosis ACP-204 | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Recruiting | 126 | Feb 2029 | Registry ↗ |
| Nov 4, 2026 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis NCT07029581 · Lewy Body Dementia Psychosis ACP-204, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Recruiting | 180 | Feb 2028 | Registry ↗ |
| Nov 4, 2026 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study NCT06194799 · Alzheimer's Disease Psychosis ACP-204 | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Enrolling by invitation | 752 | Apr 2029 | Registry ↗ |
| Oct 15, 2026 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome NCT06173531 · Hyperphagia in Prader-Willi Syndrome Carbetocin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 175 | Aug 19, 2025 | Registry ↗ |
| Aug 17, 2026 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome NCT06420297 · Hyperphagia in Prader-Willi Syndrome Carbetocin | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | 168 | Dec 19, 2025 | Registry ↗ |
| Dec 3, 2025 | Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder NCT05555615 · Irritability Associated With Autism Spectrum Disorder Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 2/3 | Terminated | 209 | Feb 14, 2025 | Registry ↗ |
| Aug 24, 2025 | Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder NCT05523895 · Irritability Associated With Autism Spectrum Disorder Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2/3 | Completed | 237 | Sep 27, 2024 | Registry ↗ |
| Aug 24, 2025 | Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia NCT03121586 · Schizophrenia Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | 995 | Apr 30, 2024 | Registry ↗ |
| Aug 22, 2025 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophre… NCT04531982 · Schizophrenia Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 454 | Jan 25, 2024 | Registry ↗ |
| Jan 20, 2025 | ACP-104 in Acutely Psychotic Subjects With Schizophrenia NCT00490516 · Schizophrenia ACP-104, ACP-104 | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 247 | Feb 2008 | Registry ↗ |
| Jan 14, 2025 | Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disea… NCT04292223 · Parkinson Disease Psychosis Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 4 | Completed | 29 | Apr 26, 2022 | Registry ↗ |
| Jan 9, 2025 | Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of… NCT05008835 · Osteoarthritis Pain ACP-044 Dose A, ACP-044 Dose B | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Terminated | 61 | Oct 6, 2022 | Registry ↗ |
| Dec 31, 2024 | A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms… NCT03575052 · Neuropsychiatric Symptoms Related to Neurodegenerative Dise… Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 784 | May 6, 2022 | Registry ↗ |
| Dec 20, 2024 | Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurode… NCT03623321 · Neuropsychiatric Symptoms Related to Neurodegenerative Dise… Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 595 | May 5, 2023 | Registry ↗ |
| Sep 27, 2024 | Open-Label Extension Study of Trofinetide for Rett Syndrome NCT04776746 · Rett Syndrome trofinetide | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | 77 | Jun 30, 2023 | Registry ↗ |
| Sep 24, 2024 | An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Ret… NCT04988867 · Rett Syndrome Trofinetide | ACAD ACADIA Pharmaceuticals Inc. | Phase 2/3 | Terminated | 15 | May 31, 2023 | Registry ↗ |
| Apr 11, 2024 | Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome NCT04279314 · Rett Syndrome Trofinetide | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 154 | Aug 19, 2022 | Registry ↗ |
| Apr 8, 2024 | Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™) NCT04181723 · Rett Syndrome Trofinetide, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 187 | Oct 28, 2021 | Registry ↗ |
| May 3, 2023 | Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following… NCT04855240 · Acute Postoperative Pain, Bunionectomy ACP-044 Dose A, ACP-044 Dose B | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 239 | Feb 11, 2022 | Registry ↗ |
| Apr 5, 2022 | Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response… NCT04000009 · Adjunctive Treatment of Major Depressive Disorder Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Terminated | 235 | Feb 22, 2021 | Registry ↗ |
| Nov 17, 2021 | Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antid… NCT03968159 · Adjunctive Treatment of Major Depressive Disorder Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 298 | Apr 30, 2020 | Registry ↗ |
| Oct 14, 2021 | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychi… NCT04164758 · Parkinson's Disease Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Terminated | 11 | Sep 25, 2020 | Registry ↗ |
| Aug 6, 2021 | The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study NCT03152292 · Parkinson Disease Psychosis Real-world, non-interventional | ACAD ACADIA Pharmaceuticals Inc. | — | Terminated | 764 | Mar 8, 2021 | Registry ↗ |
| Jun 21, 2021 | Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis NCT03325556 · Dementia-related Psychosis Placebo, Pimavanserin 34 mg | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 392 | Jul 31, 2019 | Registry ↗ |
| Dec 22, 2020 | Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophre… NCT02970305 · Schizophrenia Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 403 | Oct 16, 2019 | Registry ↗ |
| Nov 23, 2020 | An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients NCT01518309 · Parkinson's Disease Psychosis pimavanserin tartrate (ACP-103) | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 39 | May 2, 2013 | Registry ↗ |
| Aug 31, 2020 | Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression NCT03482882 · Treatment of Depression in Adults With Parkinson's Disease… Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 47 | Jul 9, 2019 | Registry ↗ |
| Jun 17, 2020 | Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1) NCT02970292 · Schizophrenia Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 396 | May 28, 2019 | Registry ↗ |
| Apr 9, 2020 | A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's… NCT03118947 · Agitation and Aggression in Alzheimer's Disease Pimavanserin | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 79 | Feb 25, 2019 | Registry ↗ |
| Nov 14, 2019 | Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (… NCT03018340 · Adjunctive Treatment of Major Depressive Disorder Pimavanserin, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 207 | Sep 2018 | Registry ↗ |
| Jun 24, 2019 | A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disea… NCT00550238 · Parkinson's Disease Psychosis Pimavanserin tartrate (ACP-103) | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 459 | May 30, 2018 | Registry ↗ |
| Mar 28, 2019 | Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggress… NCT02992132 · Agitation and Aggression in Alzheimer's Disease Pimavanserin 34 mg, Pimavanserin 20 mg | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Terminated | 111 | Jan 25, 2018 | Registry ↗ |
| Oct 25, 2017 | A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis NCT02035553 · Alzheimer's Disease Psychosis Pimavanserin tartrate, Placebo | ACAD ACADIA Pharmaceuticals Inc. | Phase 2 | Completed | 181 | Sep 28, 2016 | Registry ↗ |
| May 19, 2017 | A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psych… NCT00658567 · Parkinson's Disease Psychosis Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP… | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 123 | Dec 2009 | Registry ↗ |
| May 17, 2017 | A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease P… NCT00477672 · Parkinson's Disease Psychosis Pimavanserin tartrate (ACP-103), Pimavanserin tartrate (ACP… | ACAD ACADIA Pharmaceuticals Inc. | Phase 3 | Completed | 298 | Jun 2009 | Registry ↗ |
| Apr 18, 2017 | Expanded Access of Pimavanserin for Patients With PD Psychosis NCT02762591 · Parkinson's Disease Psychosis Pimavanserin tartrate | ACAD ACADIA Pharmaceuticals Inc. | — | Approved for marketing | — | — | Registry ↗ |
38 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:31 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances